Theodore C. Tarver

ORCID: 0000-0002-2058-7609

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations”.

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Blood Advances(2020)10.1182/bloodadvances.2019000919

N/A

0DataRank · unranked

78 citations

Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori +2 more

Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3458

N/A

0DataRank · unranked

16 citations

Aaron D. Viny, Evan Massi, Cyriac Kandoth, Nicholas D. Socci, Franck Rapaport +12 more

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101290

N/A

0DataRank · unranked

12 citations

Carlos Stahlhut, Theodore C. Tarver, Sydney Wishner, Bianca J. Lee, Cheryl A.C. Peretz +12 more